ストックスクリーナーアプリを入手
10.10
2.96%
0.29
アフターアワーズ：
10.05
-0.05
-0.50%
前日終値:
$9.81
開ける：
$9.83
24時間の取引高:
2.17M
Relative Volume:
0.51
時価総額：
$641.36M
収益：
-
当期純損益:
$-145.21M
株価収益率:
-4.3913
EPS:
-2.3
ネットキャッシュフロー:
$-140.12M
1週間 パフォーマンス:
+6.09%
1か月 パフォーマンス:
+40.86%
6か月 パフォーマンス:
-76.00%
1年 パフォーマンス:
-78.24%
1日の値動き範囲:
$9.70
$10.13
1週間の範囲:
$9.37
$10.40
52週間の値動き範囲:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
MLTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
10.10 | 622.95M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-02 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | ダウングレード | Goldman | Buy → Neutral |
| 2025-09-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-09-30 | ダウングレード | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-09-29 | ダウングレード | Jefferies | Buy → Hold |
| 2025-09-29 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | ダウングレード | Stifel | Buy → Hold |
| 2025-07-28 | 開始されました | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2024-11-05 | 再開されました | Wedbush | Outperform |
| 2024-08-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-02 | 開始されました | Goldman | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Citigroup | Buy |
| 2023-11-02 | 開始されました | Stifel | Buy |
| 2023-09-14 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 開始されました | Needham | Buy |
| 2023-06-15 | 開始されました | Barclays | Equal Weight |
| 2023-05-01 | 開始されました | Guggenheim | Buy |
| 2023-03-22 | 開始されました | Wedbush | Outperform |
| 2023-03-09 | 開始されました | BTIG Research | Buy |
| 2023-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 開始されました | Bryan Garnier | Buy |
| 2022-11-11 | 開始されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | SVB Leerink | Outperform |
| 2022-07-21 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-07 | 開始されました | Cowen | Outperform |
すべてを表示
Moonlake Immunotherapeutics (MLTX) 最新ニュース
MoonLake Immunotherapeutics Class Action: MLTX Stockholders Shou - GuruFocus
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading 6.7% HigherShould You Buy? - MarketBeat
MoonLake Immunotherapeutics Class Action: MLTX Stockholders Should Contact Robbins LLP for Information About the Class Action Against - PR Newswire
Levi & Korsinsky Notifies MoonLake Immunotherapeutics (MLTX) InvestorsLead Plaintiff Deadline on December 15, 2025 - Barchart.com
MLTX Investors Have Opportunity to Lead MoonLake - GlobeNewswire
MoonLake Immunotherapeutics (MLTX) Faces Securities Class - GlobeNewswire
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
DEADLINE ALERT for ATYR, MLTX, BAX: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Newsfile
Bragar Eagel & Squire, P.C. Reminds Investors of aTyr, - GlobeNewswire
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - Business Wire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in MoonLake Immunotherapeutics of Class Action Lawsuit and Upcoming DeadlinesMLTX - FinancialContent
MLTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ... - Bluefield Daily Telegraph
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER - GlobeNewswire
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate — Hagens Berman - Morningstar
The Gross Law Firm Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming DeadlineMLTX - MarketScreener
MoonLake Immunotherapeutics (MLTX) Projected to Post Earnings on Thursday - MarketBeat
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) - openPR.com
Deadline Approaching: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith - MarketScreener
Shareholders SueWallSt in New Class Action Against MoonLake ImmunotherapeuticsAct Now - Nasdaq
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire
MLTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
MOONLAKE IMMUNOTHERAPEUTICS SECURITIES FRAUD NOTICE: Berger Montague Informs MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors of Securities Fraud Lawsuit - Your Wyoming Link
Is MoonLake Immunotherapeutics stock resilient to inflationWeekly Trading Summary & Reliable Breakout Stock Forecasts - Fundação Cultural do Pará
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit - Morningstar
MoonLake Immunotherapeutics Sued for Securities Law - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages MoonLake - GlobeNewswire
How supply chain issues affect MoonLake Immunotherapeutics stockWeekly Investment Report & Safe Capital Investment Plans - Fundação Cultural do Pará
Law Offices of Frank R. Cruz Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action - MarketScreener
Levi & Korsinsky Notifies Shareholders of MoonLake Immunotherapeutics (MLTX) of a Class Action Lawsuit and an Upcoming Deadline - NewMediaWire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - MarketScreener
Oppenheimer Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
Levi & Korsinsky Notifies Shareholders of MoonLake Immunotherapeutics(MLTX) of a Class Action Lawsuit and an Upcoming Deadline - MarketScreener
SHAREHOLDER ALERT: MoonLake Immunotherapeutics (NASDAQ:MLTX) Faces Securities Class Action after 90% Stock Drop; Contact BFA Law by December 15 Legal Deadline - GlobeNewswire
Will MoonLake Immunotherapeutics stock pay special dividendsEarnings Performance Report & Weekly Watchlist for Consistent Profits - Fundação Cultural do Pará
Is MoonLake Immunotherapeutics stock positioned for digital transformationWeekly Trade Summary & Reliable Breakout Forecasts - Fundação Cultural do Pará
Can MoonLake Immunotherapeutics stock beat analyst upgrades2025 Momentum Check & Risk Controlled Stock Pick Alerts - newser.com
SHAREHOLDER ALERT: DiCello Levitt LLP Announces That A - GlobeNewswire
Moonlake Immunotherapeutics Advances Psoriatic Arthritis Treatment with Sonelokimab Study - TipRanks
Moonlake Immunotherapeutics Advances in Hidradenitis Suppurativa Treatment with Sonelokimab Study - TipRanks
MoonLake Stockholders with Large Losses are Encouraged to - GlobeNewswire
Guidance Update: Why MoonLake Immunotherapeutics stock is in analyst buy zoneTrade Entry Report & AI Enhanced Execution Alerts - Fundação Cultural do Pará
MLTX FRAUD NOTICE: BFA Law Notifies MoonLake Immunotherapeutics Shareholders of Filed Securities Fraud Class Action; Investor Deadline December 15 - ACCESS Newswire
MoonLake’s Promising Phase 3 Study on Sonelokimab for Psoriatic Arthritis - TipRanks
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action - Business Wire
Moonlake Immunotherapeutics (MLTX) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):